Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

HIV Ag/Ab Combo ECLIA Test Methodology

Specimen Requirements and Processing

  • The Centers for Disease Control and Prevention recommends that the test requires serum or plasma collected in standard blood collection tubes with EDTA, citrate, or heparin as acceptable anticoagulants 1
  • A minimum volume of 100 μL of specimen is typically required for automated ECLIA platforms 1

Pre-Analytical Considerations

  • The Centers for Disease Control and Prevention suggests that specimens should be centrifuged at no greater than 400g for 3-5 minutes to separate serum or plasma from cellular components 2
  • Samples can be stored at refrigerator temperatures (4-10°C) for up to 24 hours before testing, or frozen at -70°C for longer-term storage 2

Testing Algorithm and Workflow

  • The Centers for Disease Control and Prevention recommends that all initially reactive specimens must be retested in duplicate using the same ECLIA assay 3, 4
  • A specimen is considered repeatedly reactive only if at least one of the duplicate retests is reactive 3, 4

Confirmatory Testing Pathway

  • The Centers for Disease Control and Prevention recommends that repeatedly reactive specimens by HIV-1/HIV-2 ECLIA must be tested by HIV-1 Western blot or another licensed supplemental test for confirmation 3, 4, 5
  • If the HIV-1 Western blot result is positive, this confirms the presence of HIV antibodies and no further testing is needed unless HIV-2 risk factors are present 3, 4

Quality Control and Validation

  • The Centers for Disease Control and Prevention suggests that each ECLIA run must include negative and positive controls to ensure assay validity 2
  • The run is considered valid only when all controls fall within acceptable ranges with no false positives in negative controls or false negatives in positive controls 2, 7

Clinical Interpretation Caveats

  • The Centers for Disease Control and Prevention notes that antibody tests cannot rule out infection that occurred less than 6 months before testing, as HIV antibody is detectable in ≥95% of patients within 6 months of infection 6
  • Acute HIV infection within the first 2-4 weeks may yield negative ECLIA results despite active viral replication 6

Special Populations

  • The Centers for Disease Control and Prevention recommends that for infants <15 months of age, definitive diagnosis must be based on virologic testing (HIV DNA or RNA PCR) rather than antibody testing due to maternal antibody transfer 6
  • ECLIA antibody results in this population reflect maternal rather than infant infection status 6
  • HIV-2 testing should be considered in persons from endemic regions (West Africa, Portugal, France, India) or their sexual partners 6
  • Testing for HIV-2 is recommended when clinical evidence of HIV disease exists but HIV-1 antibody tests are negative 6
  • If HIV-1 Western blot shows an unusual indeterminate pattern (gag plus pol bands without env bands), HIV-2-specific testing should be performed 3, 4